Cardiopulmonary bypass and thyroid hormone metabolism.

Abstract

Early investigations involving patient response to thyrotropin-releasing hormone during cardiac operations prompted researchers to consider that the cardiopulmonary bypass (CPB) procedure may affect this response. Results from several studies indicate that total T3 (active thyroid hormone) concentrations are significantly reduced during and after CPB (ie, the euthyroid sick syndrome). Inhibition of the monodeiodinase pathway during CPB, and subsequent inhibition of peripheral thyroxine to T3 conversion may partly explain these findings. These data prompted the investigation of intravenous T3 administration to patients undergoing CPB. Clinical trials to date have shown that intravenous T3 administered during or after CPB improves cardiac output and contractility. This article reviews the studies of thyroid hormone before, during, and after CPB operations.